Total Liabilities Summary of Haemonetics Corporation

Haemonetics Corporation's latest annual total liabilities in 2024 was 1.23 Billion USD , up 10.64% from previous year.
Haemonetics Corporation's latest quarterly total liabilities in 2024 FY was 1.23 Billion USD , up 10.64% from previous quarter.
Haemonetics Corporation reported annual total liabilities of 1.11 Billion USD in 2023, up 0.59% from previous year.
Haemonetics Corporation reported annual total liabilities of 1.11 Billion USD in 2022, up 2.03% from previous year.
Haemonetics Corporation reported quarterly total liabilities of 1.11 Billion USD for 2024 Q2, up 1.82% from previous quarter.
Haemonetics Corporation reported quarterly total liabilities of 1.09 Billion USD for 2024 Q1, down -1.72% from previous quarter.

Annual Total Liabilities Chart of Haemonetics Corporation (2024 - 1992)

Historical Annual Total Liabilities of Haemonetics Corporation (2024 - 1992)

Year	Total Liabilities	Total Liabilities Growth
2024	1.23 Billion USD	10.64%
2023	1.11 Billion USD	0.59%
2022	1.11 Billion USD	2.03%
2021	1.08 Billion USD	60.04%
2020	680 Million USD	12.05%
2019	606.89 Million USD	25.16%
2018	484.91 Million USD	-2.84%
2017	499.09 Million USD	-16.42%
2016	597.12 Million USD	-9.11%
2015	656.99 Million USD	-3.56%
2014	681.23 Million USD	-1.65%
2013	692.68 Million USD	294.57%
2012	175.55 Million USD	19.32%
2011	147.12 Million USD	-8.63%
2010	161.01 Million USD	46.64%
2009	109.8 Million USD	-4.32%
2008	114.76 Million USD	23.28%
2007	93.08 Million USD	-11.26%
2006	104.89 Million USD	-6.86%
2005	112.62 Million USD	-11.77%
2004	127.64 Million USD	-6.12%
2003	135.97 Million USD	6.15%
2002	128.09 Million USD	-1.31%
2001	129.79 Million USD	-9.02%
2000	142.66 Million USD	6.07%
1999	134.5 Million USD	-5.28%
1998	142 Million USD	44.6%
1997	98.2 Million USD	38.7%
1996	70.8 Million USD	-18.9%
1995	87.3 Million USD	24.89%
1994	69.9 Million USD	30.41%
1993	53.6 Million USD	-1.11%
1992	54.2 Million USD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 FY	1.23 Billion USD	10.64%
2024 Q2	1.11 Billion USD	1.82%
2024 Q1	1.09 Billion USD	-1.72%
2024 Q3	1.25 Billion USD	12.48%
2024 Q4	1.23 Billion USD	-1.71%
2023 Q4	1.11 Billion USD	1.34%
2023 Q2	1.13 Billion USD	8.19%
2023 Q3	1.1 Billion USD	-2.99%
2023 Q1	1.05 Billion USD	-5.42%
2023 FY	1.11 Billion USD	0.59%
2022 Q4	1.11 Billion USD	0.88%
2022 Q2	1.1 Billion USD	-1.27%
2022 Q1	1.11 Billion USD	2.65%
2022 FY	1.11 Billion USD	2.03%
2022 Q3	1.1 Billion USD	-0.21%
2021 FY	1.08 Billion USD	60.04%
2021 Q1	824.6 Million USD	21.27%
2021 Q2	750.25 Million USD	-9.02%
2021 Q3	598.91 Million USD	-20.17%
2021 Q4	1.08 Billion USD	81.7%
2020 Q3	663.16 Million USD	9.29%
2020 Q2	606.78 Million USD	-9.25%
2020 Q1	668.64 Million USD	10.17%
2020 FY	680 Million USD	12.05%
2020 Q4	680 Million USD	2.54%
2019 Q4	606.89 Million USD	3.83%
2019 Q2	564.37 Million USD	-0.48%
2019 FY	606.89 Million USD	25.16%
2019 Q1	567.1 Million USD	16.95%
2019 Q3	584.5 Million USD	3.57%
2018 Q4	484.91 Million USD	-0.82%
2018 Q1	478.61 Million USD	-4.1%
2018 FY	484.91 Million USD	-2.84%
2018 Q2	469.91 Million USD	-1.82%
2018 Q3	488.9 Million USD	4.04%
2017 Q1	601.83 Million USD	0.79%
2017 Q3	535.52 Million USD	-8.57%
2017 Q2	585.71 Million USD	-2.68%
2017 Q4	499.09 Million USD	-6.8%
2017 FY	499.09 Million USD	-16.42%
2016 Q2	642.06 Million USD	0.99%
2016 Q1	635.76 Million USD	-3.23%
2016 Q3	616.87 Million USD	-3.92%
2016 Q4	597.12 Million USD	-3.2%
2016 FY	597.12 Million USD	-9.11%
2015 Q4	656.99 Million USD	3.0%
2015 Q1	661.65 Million USD	-2.87%
2015 Q2	653.82 Million USD	-1.18%
2015 Q3	637.89 Million USD	-2.44%
2015 FY	656.99 Million USD	-3.56%
2014 FY	681.23 Million USD	-1.65%
2014 Q4	681.23 Million USD	2.46%
2014 Q3	664.86 Million USD	-3.24%
2014 Q2	687.11 Million USD	-2.57%
2014 Q1	705.25 Million USD	1.81%
2013 Q3	695.21 Million USD	1.85%
2013 FY	692.68 Million USD	294.57%
2013 Q4	692.68 Million USD	-0.36%
2013 Q1	170.65 Million USD	-4.4%
2013 Q2	682.58 Million USD	299.98%
2012 Q3	142.54 Million USD	-2.0%
2012 FY	175.55 Million USD	19.32%
2012 Q2	145.44 Million USD	3.19%
2012 Q1	140.95 Million USD	-4.2%
2012 Q4	178.5 Million USD	25.23%
2011 Q3	134.86 Million USD	-5.92%
2011 Q1	129.2 Million USD	-22.88%
2011 FY	147.12 Million USD	-8.63%
2011 Q4	147.12 Million USD	9.09%
2011 Q2	143.34 Million USD	10.94%
2010 FY	161.01 Million USD	46.64%
2010 Q4	167.53 Million USD	29.74%
2010 Q3	129.13 Million USD	-4.25%
2010 Q2	134.86 Million USD	5.29%
2010 Q1	128.09 Million USD	16.65%
2009 Q4	109.8 Million USD	3.05%
2009 FY	109.8 Million USD	-4.32%
2009 Q3	106.56 Million USD	2.57%
2009 Q1	114.29 Million USD	-0.4%
2009 Q2	103.89 Million USD	-9.1%
2008 Q4	114.76 Million USD	24.97%
2008 FY	114.76 Million USD	23.28%
2008 Q1	101.54 Million USD	9.09%
2008 Q2	100.96 Million USD	-0.58%
2008 Q3	91.83 Million USD	-9.04%
2007 Q1	106.39 Million USD	1.44%
2007 Q3	96.52 Million USD	-7.58%
2007 FY	93.08 Million USD	-11.26%
2007 Q4	93.08 Million USD	-3.56%
2007 Q2	104.44 Million USD	-1.84%
2006 Q3	104.16 Million USD	-6.97%
2006 FY	104.89 Million USD	-6.86%
2006 Q2	111.97 Million USD	-1.17%
2006 Q1	113.29 Million USD	0.6%
2006 Q4	104.89 Million USD	0.7%
2005 FY	112.62 Million USD	-11.77%
2005 Q4	112.62 Million USD	-6.8%
2005 Q1	121.75 Million USD	-4.62%
2005 Q2	117.86 Million USD	-3.19%
2005 Q3	120.83 Million USD	2.52%
2004 Q2	134.53 Million USD	0.59%
2004 FY	127.64 Million USD	-6.12%
2004 Q3	132.33 Million USD	-1.64%
2004 Q4	127.64 Million USD	-3.54%
2004 Q1	133.74 Million USD	-1.64%
2003 Q1	136.3 Million USD	6.41%
2003 Q3	144.65 Million USD	1.53%
2003 Q2	142.48 Million USD	4.53%
2003 FY	135.97 Million USD	6.15%
2003 Q4	135.97 Million USD	-6.01%
2002 Q2	144.67 Million USD	7.64%
2002 Q3	133.13 Million USD	-7.98%
2002 Q1	134.4 Million USD	3.55%
2002 Q4	128.09 Million USD	-3.78%
2002 FY	128.09 Million USD	-1.31%
2001 Q2	133.47 Million USD	3.42%
2001 Q1	129.05 Million USD	-9.54%
2001 Q3	141.23 Million USD	5.82%
2001 FY	129.79 Million USD	-9.02%
2001 Q4	129.79 Million USD	-8.1%
2000 Q4	142.66 Million USD	-4.76%
2000 Q2	133.6 Million USD	6.28%
2000 Q3	149.8 Million USD	12.13%
2000 Q1	125.7 Million USD	-6.54%
2000 FY	142.66 Million USD	6.07%
1999 Q4	134.5 Million USD	2.28%
1999 Q1	132.2 Million USD	-6.9%
1999 Q2	132.2 Million USD	0.0%
1999 Q3	131.5 Million USD	-0.53%
1999 FY	134.5 Million USD	-5.28%
1998 FY	142 Million USD	44.6%
1998 Q2	135.5 Million USD	13.48%
1998 Q3	140.3 Million USD	3.54%
1998 Q4	142 Million USD	1.21%
1998 Q1	119.4 Million USD	21.59%
1997 FY	98.2 Million USD	38.7%
1997 Q4	98.2 Million USD	25.26%
1997 Q1	70.3 Million USD	-0.71%
1997 Q2	73.7 Million USD	4.84%
1997 Q3	78.4 Million USD	6.38%
1996 FY	70.8 Million USD	-18.9%
1996 Q2	83.6 Million USD	-3.24%
1996 Q1	86.4 Million USD	-1.03%
1996 Q4	70.8 Million USD	-3.67%
1996 Q3	73.5 Million USD	-12.08%
1995 FY	87.3 Million USD	24.89%
1995 Q4	87.3 Million USD	17.65%
1995 Q1	64.4 Million USD	-7.87%
1995 Q3	74.2 Million USD	2.77%
1995 Q2	72.2 Million USD	12.11%
1994 FY	69.9 Million USD	30.41%
1994 Q2	58.1 Million USD	13.48%
1994 Q3	57.4 Million USD	-1.2%
1994 Q4	69.9 Million USD	21.78%
1994 Q1	51.2 Million USD	-4.48%
1993 Q3	46.4 Million USD	-7.75%
1993 Q2	50.3 Million USD	-3.45%
1993 Q4	53.6 Million USD	15.52%
1993 Q1	52.1 Million USD	-3.87%
1993 FY	53.6 Million USD	-1.11%
1992 Q3	61.9 Million USD	14.42%
1992 FY	54.2 Million USD	0.0%
1992 Q4	54.2 Million USD	-12.44%
1992 Q1	46.3 Million USD	0.0%
1992 Q2	54.1 Million USD	16.85%

Peer Total Liabilities Comparison of Haemonetics Corporation

Name	Total Liabilities	Total Liabilities Difference
Alcon Inc.	8.98 Billion USD	86.251%
AptarGroup, Inc.	2.13 Billion USD	42.005%
Baxter International Inc.	19.8 Billion USD	93.762%
Becton, Dickinson and Company	26.98 Billion USD	95.421%
Bausch + Lomb Corporation	6.52 Billion USD	81.054%
Envista Holdings Corp	2.43 Billion USD	49.176%
ResMed Inc.	2 Billion USD	38.475%
Teleflex Incorporated	3.09 Billion USD	60.032%
Warby Parker Inc.	278.52 Million USD	-343.634%
West Pharmaceutical Services, Inc.	948.5 Million USD	-30.272%

Global Stocks Search

Haemonetics Corporation (HAE)

Total Liabilities Summary of Haemonetics Corporation

Annual Total Liabilities Chart of Haemonetics Corporation (2024 - 1992)

Historical Annual Total Liabilities of Haemonetics Corporation (2024 - 1992)

Peer Total Liabilities Comparison of Haemonetics Corporation